ZeroStack (ZSTK) Stock Price, Financials & Analysis

Key Stats

Market Cap38.85 Mn

P/E-0.22

P/S0.97

Div. Yield0.00

Total Debt (Qtr)2.41 Mn

Revenue Growth (1y) (Qtr)40.67

Add ratio to table…

About

ZeroStack Corp. is an asset management and pharmaceutical distribution company that integrates artificial intelligence, digital assets, and global wholesale operations. The company operates at the intersection of decentralized AI infrastructure and traditional pharmaceutical markets, positioning itself as a hybrid player in emerging and established industries. ZeroStack’s strategy centers on accumulating and managing digital assets, particularly 0G Tokens, while…

The company generates revenue primarily through its pharmaceutical distribution segment, which supplies a range of prescription medications, including cancer therapies, ADHD treatments, multiple sclerosis drugs, and antidepressants. In its digital assets segment, ZeroStack does not yet derive direct revenue but aims to create long-term value through strategic holdings, staking activities, and AI-driven asset management. The company’s treasury strategy involves accumulating cryptocurrencies, such as 0G and Bitcoin, with plans to leverage these assets for future income generation or capital appreciation.

The company operates through the following segments:

Digital Assets and AI: This segment focuses on building and managing a treasury of digital assets, with a long-term strategy centered on accumulating 0G Tokens. ZeroStack intends to hold these assets for capital appreciation and explore revenue-accretive opportunities, such as staking and AI-driven asset management. The segment also monitors regulatory developments to ensure compliance while pursuing growth in decentralized AI infrastructure.
Commercial and Wholesale: This segment encompasses the distribution of pharmaceutical products, primarily through Phatebo GmbH, which operates in Germany. Phatebo imports and exports a wide range of medications, serving healthcare providers, pharmacies, and patients across Europe. The segment leverages Germany’s position as a leading pharmaceutical market to drive revenue and expand its product offerings.

ZeroStack Corp. occupies a unique position in both the digital assets and pharmaceutical industries. In the digital assets space, the company competes with larger treasury management firms, blockchain protocols, and AI-focused asset managers. Its competitive advantage lies in its early adoption of 0G Tokens and its focus on decentralized AI infrastructure, which aligns with growing demand for scalable, verifiable AI solutions. In the pharmaceutical distribution market, ZeroStack benefits from Phatebo’s established operations in Germany, a key hub for pharmaceutical sales in Europe. The company’s hybrid model allows it to diversify risk while capitalizing on high-growth opportunities in AI and blockchain.

The company’s customer base is divided between its two core segments. In pharmaceutical distribution, ZeroStack serves hospitals, pharmacies, and healthcare providers across Europe, with a strong presence in Germany. The digital assets segment does not yet have a direct customer base but targets institutional and retail investors interested in decentralized AI and blockchain technologies. Specific customer names are not disclosed in the filing.

How ZeroStack ranks

Ranked against the 27 companies in Healthcare Payers and Distributors58 metrics · as of Oct 16, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −0.24xMedian 25.1x 4^th
P/FCFNegative free cash flow −7.45xMedian 15.8x 22^nd
P/Operating cash flowNegative operating cash flow −7.51xMedian 13.6x 18^th
P/S 1.05xMedian 0.36x 17^th
P/B 3.04xMedian 2.67x 42^nd
P/Tangible book 3.04xMedian 3.13x 56^th
EV/EBITDANegative EBITDA −0.17xMedian 14.3x 1^st
EV/EBITNegative EBIT −0.17xMedian 19.2x 1^st
EV/Revenue 1.04xMedian 0.40x 18^th
EV/FCFNegative free cash flow −7.41xMedian 17.4x 14^th
EV/Operating cash flowNegative operating cash flow −7.46xMedian 15.4x 14^th
PEG (3Y EPS CAGR)Negative earnings 0.00Median 1.37 Not meaningful —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) 27.3%Median 7.8% 77^th
Revenue CAGR (3Y) −13.1%Median 9.1% 10^th
Gross profit growth (1Y) 172%Median 11.2% 95^th
Gross profit CAGR (3Y) −32.4%Median 6.4% 1^st
Operating income growth (1Y) −2,574%Median −0.4% 1^st
Operating income CAGR (3Y) −57.0%Median 7.0% 9^th
Net income growth (1Y) −1,263%Median 9.2% 1^st
Net income CAGR (3Y) −37.3%Median 0.8% 14^th
EPS growth (1Y) 24.9%Median 20.8% 52^nd
EPS CAGR (3Y) 64.4%Median 12.0% 96^th
Operating cash flow growth (1Y) 37.6%Median 31.3% 57^th
Operating cash flow CAGR (3Y) 23.9%Median 9.3% 73^rd
Free cash flow growth (1Y) 37.9%Median 31.9% 52^nd
Free cash flow CAGR (3Y) 25.2%Median 11.3% 73^rd

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin 13.1%Median 16.1% 43^rd
EBITDA margin −597%Median 1.6% 1^st
Operating margin −598%Median 1.0% 1^st
Pretax margin −436%Median 1.0% 1^st
Net margin −444%Median 0.8% 1^st
FCF margin −14.1%Median 2.1% 17^th
Operating cash flow margin −14.0%Median 2.4% 17^th
Return on equity −703%Median 7.1% 1^st
Return on assets −505%Median 2.2% 4^th
Return on invested capital −852%Median 6.9% 1^st
Return on capital employed −994%Median 6.9% 1^st
Asset turnover 1.14xMedian 2.15x 13^th
Cash conversion (OCF / net income)Net income is not positive 0.03xMedian 1.82x Not meaningful —
Stock comp / revenue 13.1%Median 0.6% 11^th

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets 9.6%Median 20.8% 85^th
Debt / equity 0.17xMedian 0.74x 86^th
Net debt / EBITDAEBITDA is not positive 0.00xMedian 1.37x Not meaningful —
Debt / FCFFree cash flow is not positive −0.43xMedian 3.30x Not meaningful —
Liabilities / assets 45.1%Median 70.6% 80^th
Equity / assets 54.9%Median 29.4% 80^th
Interest coverage —Median 2.08x No data —
Current ratio 0.95xMedian 1.11x 36^th
Quick ratio 0.71xMedian 0.86x 40^th
Cash ratio 0.24xMedian 0.41x 44^th
Altman Z-score −46.4Median 2.82 4^th

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	UNH	Unitedhealth Group Inc	367.15 Bn	26.00	0.82	73.33 Bn
2	MCK	Mckesson Corp	120.04 Bn	26.14	0.29	9.73 Bn
3	CVS	CVS HEALTH Corp	118.50 Bn	24.23	0.29	61.41 Bn
4	ELV	Elevance Health, Inc.	93.30 Bn	18.80	0.46	31.04 Bn
5	CI	Cigna Group	78.69 Bn	12.19	0.28	31.88 Bn
6	COR	Cencora, Inc.	65.67 Bn	25.02	0.20	11.72 Bn
7	CAH	Cardinal Health Inc	59.70 Bn	34.83	0.23	8.89 Bn
8	ZSTK	ZeroStack Corp.	0.04 Bn	-0.22	0.97	0.00 Bn

ZeroStack ZSTK

About

How ZeroStack ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

ZeroStack ZSTK

About

How ZeroStack ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password